A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.

PHASE1TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Ulcerative Colitis
Interventions
DRUG

mesalamine

oral tablet, 30 mg mesalamine/day for 28 days

DRUG

mesalamine

oral tablet, 60 mg mesalamine/day for 28 days

DRUG

mesalamine

oral tablet, 90 mg mesalamine/day for 28 days

Trial Locations (22)

14222

Research Site, Buffalo

21114

Research Site, Boston

21287

Research Site, Baltimore

29615

Research Site, Greenville

32207

Research Site, Jacksonville

32610

Research Site, Gainesville

35203

Research Site, Birmingham

44106

Research Site, Cleveland

45229

Research Site, Cincinnati

48236

Research Site, Detroit

60068

Research Site, Park Ridge

63304

Research Site, Mobile

68105

Research Site, Omaha

75235

Research Site, Dallas

77030

Research Site, Houston

77504

Research Site, Pasadena

92103

Research Site, San Diego

92626

Research Site, Costa Mesa

94143

Research Site, San Francisco

97239

Research Site, Portland

98105

Research Site, Seattle

07962

Research Site, Morristown

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Warner Chilcott

INDUSTRY

NCT00254618 - A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis. | Biotech Hunter | Biotech Hunter